Alvarez-Lopez, I. http://orcid.org/0000-0001-8958-0694
Bezares, S.
Dalmau Portulas, E.
García-Martínez, E.
García-Sáenz, J. Á.
Gil-Gil, M.
Martínez de Dueñas, E.
Ribelles, N.
Santaballa Bertrán, A.
Funding for this research was provided by:
Novartis Farmacéutica
Article History
Received: 30 October 2019
Accepted: 8 December 2019
First Online: 12 February 2020
Compliance with ethical standards
:
: IMAL declares consultancy/speaker fees from Novartis, Pfizer, Palex and Roche, institution research funding from Astra Zeneca, Roche, Novartis and Pfizer and travel support from Roche, Pfizer and Eisai. JAGS declares consultancy/speaker fees from Novartis, Celgene, Eli Lilly, EISAI and Roche, institution research funding from Astra Zeneca and travel support from Novartis, Roche and Pfizer. MGG declares personal fees from Novartis, Pfizer, Genomic Health Roche, Daiichi-Sankyo and Eisai. NRE declares consultancy/speaker fees from Novartis, Roche and Pfizer and travel support from Novartis, Roche and Pfizer. SBM declares grants from Novartis to GEICAM SPANISH BREAST CANCER GROUP, during the conduct of the study. ED declares personal fees from Roche, Pfizer, Novartis, Eisai, and Lilly. EM declares consultancy/speaker fees from Novartis, EISAI, Roche and Pfizer, institution research funding from Astra Zeneca and travel support from Roche. ASB declares consultancy/speaker fees from Roche, Novartis, Astra-Zeneca, Tesaro, Clovis, Amgen, MSD and Pfizer. She also declares registration and attending scientific meetings at Pfizer, Roche, Pharmamar and MSD.
: The study has been performed in accordance with the ethical standards of the Declaration of Helsinki and its later amendments. This article does not contain any data derived from studies with human participants or animals performed by any of the authors.
: None.